[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?

Prediction market on manifold. (https://www.metaculus.com/questions/embed/41169) Resolves according to Metaculus resolution. Metaculus high-level description: This question will resolve as Yes if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other than sickle cell disease and beta thalassemia before January 1, 2027.

24h Volume: $50. Liquidity: $5,100. Resolves: 12/31/2026.